The therapeutic application of DAB389IL-2 is not limited to the treatment of T-cell derived malignant disease. DAB389IL-2 is a potential therapeutic for any disease where the underlying etiology is mediated by activated T cells, such as many autoimmune diseases. To date, the clinical studies conducted to evaluate the efficacy of Ontak for the treatment of autoimmune disease have been limited to psoriasis and rheumatoid arthritis (RA). Common examples of other T lymphocyte mediated diseases include chronic inflammatory diseases such as atopic eczema, lichen planus, alopecia areata, multiple sclerosis, systemic lupus erthematosus (SLE), myasthenia gravis, Grave's disease, and graft versus host disease (Livolsi et al., 1994). Taken in aggregate, autoimmune disease is the most prevalent human disease (Murphy and vanderSpek, 2000). The presentation of autoimmune disease ranges from mild to severe and from manageable to refractory. While most autoimmune diseases are not life threatening, patients who present with severe refractory illness are in need of novel therapeutics for the treatment of the underlying basis of their disease rather than the management of their symptoms. Furthermore, the chronic nature of autoimmune diseases represents a therapeutic challenge since many of the therapeutics used to manage symptoms are associated with a broad spectrum of adverse effects.
Was this article helpful?